Comparison of 10-day standard triple therapy and nonbismuth-containing concomitant therapy for Helicobacter pylori eradication in Korea

Kyungpook National University Medical Center0 个研究点目标入组 348 人开始时间: 待定最近更新: 2019年3月11日

试验速览

暂无简介。

•1) Either sex in age of 18 to 85
•2) Among patients with active/inactive peptic ulcer diagnosed from endoscopy, those who have come up with benign helicobacter after an examination (a rapid urease test)
•3) Among patients with no organic disorders from endoscopy but with indigestion, those who have been diagnosed with benign helicobacter after an examination (a rapid urease test) and those who are willing to get a bacteria-removal treatment
•4) Among patients who received endoscopic mucosal resection or submucosal dissection to treat gastric adenoma or early gastric cancer, those with benign helicobacter diagnosed from an examination
•5) Those who have signed a written subject consent to join the experimentation

•1) Patients who have refused to participate in the experimentation
•2) Patients who have been cured by the helicobacter eradication
•3) Patients who have taken drugs for the last two weeks which would affect a bacteria examination and treatment (proton pump inhibitor, antibiotics, H2-receptor antagonist and bismuth)
•4) Patients who are on steroids, aspirin and antithrombotic
•5) Patients who have gone through a gastric operation (a gastric mucosal resection excluded)
•6) Patients with severe heart disease, lung disease, hormonal disorder
•7) Patients with severe problems in kidney and liver
•8) Patients with blood disease
•9) Patients with cancer
•10) Expecting mother or patients with chances to be pregnant
•11) Patients who have allergies to the test drug

发起方